Literature DB >> 7864817

Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms.

M Ouellet1, M D Percival.   

Abstract

Cyclooxygenase (Cox) is a key enzyme in the biosynthesis of prostaglandins and, as such, is the target of non-steroidal anti-inflammatory drugs (NSAIDs). Two isoforms exist, being expressed constitutively (Cox-1), or inducibly in response to inflammatory mediators (Cox-2). Currently available NSAIDs inhibit both isoforms somewhat equipotently but selective Cox-2 inhibition may eliminate unwanted side effects. We have characterized the kinetic mechanisms of the interactions of purified recombinant human cyclooxygenase-1 and -2 (hCox-1, hCox-2) with the selective Cox-2 inhibitor N-(2-cyclohexyloxy-4-nitrophenyl)methanesulphonamide (NS-398) and some classical non-selective NSAIDs. NS-398, flurbiprofen, meclofenamic acid and indomethacin are time-dependent, irreversible inhibitors of hCox-2. The inhibition is consistent with a two-step process, involving an initial rapid equilibrium binding of enzyme and inhibitor, characterized by Ki, followed by the slow formation of a tightly bound enzyme-inhibitor complex, characterized by a first-order rate constant kon. NS-398 is a time-independent inhibitor of hCox-1, consistent with the formation of a reversible enzyme-inhibitor complex. Flurbiprofen, meclofenamic acid and indomethacin are also time-dependent inhibitors of hCox-1 and hence show little selectivity for one isoform over the other. Flufenamic acid is time independent towards both isoforms and is also non-selective. The high degree of selectivity of NS-398 towards Cox-2 results therefore from the difference in the nature of the time-dependency of inhibition of the two isoforms.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7864817      PMCID: PMC1136508          DOI: 10.1042/bj3060247

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.

Authors:  N Futaki; K Yoshikawa; Y Hamasaka; I Arai; S Higuchi; H Iizuka; S Otomo
Journal:  Gen Pharmacol       Date:  1993-01

2.  Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man.

Authors:  A Rane; O Oelz; J C Frolich; H W Seyberth; B J Sweetman; J T Watson; G R Wilkinson; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

3.  Purification and characterization of recombinant human cyclooxygenase-2.

Authors:  M D Percival; M Ouellet; C J Vincent; J A Yergey; B P Kennedy; G P O'Neill
Journal:  Arch Biochem Biophys       Date:  1994-11-15       Impact factor: 4.013

4.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

5.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

Authors:  D A Jones; D P Carlton; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

6.  High-level expression of active human cyclooxygenase-2 in insect cells.

Authors:  W A Cromlish; P Payette; S A Culp; M Ouellet; M D Percival; B P Kennedy
Journal:  Arch Biochem Biophys       Date:  1994-10       Impact factor: 4.013

7.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

8.  Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs.

Authors:  L H Rome; W E Lands
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

9.  Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics.

Authors:  R J Kulmacz; R B Pendleton; W E Lands
Journal:  J Biol Chem       Date:  1994-02-25       Impact factor: 5.157

10.  Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid.

Authors:  G P O'Neill; J A Mancini; S Kargman; J Yergey; M Y Kwan; J P Falgueyret; M Abramovitz; B P Kennedy; M Ouellet; W Cromlish
Journal:  Mol Pharmacol       Date:  1994-02       Impact factor: 4.436

View more
  22 in total

1.  Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).

Authors:  R García-Nieto; C Pérez; F Gago
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

2.  A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.

Authors:  M Ouellet; D Riendeau; M D Percival
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

Authors:  M C Walker; R G Kurumbail; J R Kiefer; K T Moreland; C M Koboldt; P C Isakson; K Seibert; J K Gierse
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

4.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

5.  Effects of tibolone metabolites on human endometrial cell lines in co-culture.

Authors:  Claire Barbier; Helenius J Kloosterboer; David G Kaufman
Journal:  Reprod Sci       Date:  2008-01       Impact factor: 3.060

Review 6.  Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

Authors:  J Y Jouzeau; B Terlain; A Abid; E Nédélec; P Netter
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

7.  The structural and electronical factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates.

Authors:  R Pouplana; C Pérez; J Sánchez; J J Lozano; P Puig-Parellada
Journal:  J Comput Aided Mol Des       Date:  1999-05       Impact factor: 3.686

8.  Simvastatin in combination with meclofenamic acid inhibits the proliferation and migration of human prostate cancer PC-3 cells via an AKR1C3 mechanism.

Authors:  Yoshitaka Sekine; Hiroshi Nakayama; Yoshiyuki Miyazawa; Haruo Kato; Yosuke Furuya; Seiji Arai; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuto Ito; Kazuhiro Suzuki
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

9.  Antitumor effect of meclofenamic acid on human androgen-independent prostate cancer: a preclinical evaluation.

Authors:  Alejandro D Soriano-Hernández; Hector R Galvan-Salazar; Daniel A Montes-Galindo; Alejandrina Rodriguez-Hernandez; Rafael Martinez-Martinez; Jose Guzman-Esquivel; Laura L Valdez-Velazquez; Luz M Baltazar-Rodriguez; Francisco Espinoza-Gómez; Augusto Rojas-Martinez; Rocio Ortiz-Lopez; Rafael Gonzalez-Alvarez; Ivan Delgado-Enciso
Journal:  Int Urol Nephrol       Date:  2011-06-10       Impact factor: 2.370

10.  Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.

Authors:  Marc Ouellet; Jean-Pierre Falgueyret; M David Percival
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.